How I treat the older patient with acute myeloid leukemia

Characteristics of acute myeloid leukemia with myelodysplasia-related changes: A retrospective analysis in a cohort of Chinese patients

(2014) Xiao-Qian Xu et al.   AMERICAN JOURNAL OF HEMATOLOGY

TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients

(2014) R. Bejar et al.   BLOOD

The impact of health care settings on survival time of patients with chronic myeloid leukemia

(2014) M. Lauseker et al.   BLOOD

Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation

(2014) J. M. Middeke et al.   BLOOD

Combined Molecular and Clinical Prognostic Index for Relapse and Survival in Cytogenetically Normal Acute Myeloid Leukemia

(2014) Friederike Pastore et al.   JOURNAL OF CLINICAL ONCOLOGY

DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies

(2014) A P Im et al.   LEUKEMIA

The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial

(2014) M Lazenby et al.   LEUKEMIA

The impact of abn(17p) and monosomy -5/del(5q) on the prognostic value of the monosomal karyotype in acute myeloid leukemia

(2013) D. A. Breems et al.   BLOOD

Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival

(2013) A. K. Burnett et al.   BLOOD

The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA

(2013) R. F. Schlenk et al.   BLOOD

Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia

(2013) H. D. Klepin et al.   BLOOD

Outcome of older patients with acute myeloid leukemia

(2013) Mya S. Thein et al.   CANCER

Effect of NPM1 and FLT3 Mutations on the Outcomes of Elderly Patients With Acute Myeloid Leukemia Receiving Standard Chemotherapy

(2013) Naval Daver et al.   Clinical Lymphoma Myeloma & Leukemia

A Post Hoc Sensitivity Analysis of Survival Probabilities in a Multinational Phase III Trial of Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia

(2013) Xavier G. Thomas et al.   Clinical Lymphoma Myeloma & Leukemia

Curability of Patients With Acute Myeloid Leukemia Who Did Not Undergo Transplantation in First Remission

(2013) Alan K. Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

Epigenetics Meets Genetics in Acute Myeloid Leukemia: Clinical Impact of a Novel Seven-Gene Score

(2013) Guido Marcucci et al.   JOURNAL OF CLINICAL ONCOLOGY

Declining rates of treatment-related mortality in patients with newly diagnosed AML given ‘intense’ induction regimens: a report from SWOG and MD Anderson

(2013) M Othus et al.   LEUKEMIA

Geriatric assessment in older patients with acute myeloid leukemia: A retrospective study of associated treatment and outcomes

(2013) Alexander E. Sherman et al.   LEUKEMIA RESEARCH

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia

(2012) A. Quintas-Cardama et al.   BLOOD

Acute myeloid leukemia in the real world: why population-based registries are needed

(2012) G. Juliusson et al.   BLOOD

Age-Related Prognostic Impact of Different Types ofDNMT3AMutations in Adults With Primary Cytogenetically Normal Acute Myeloid Leukemia

(2012) Guido Marcucci et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparative Analysis of the Value of Allogeneic Hematopoietic Stem-Cell Transplantation in Acute Myeloid Leukemia With Monosomal Karyotype Versus Other Cytogenetic Risk Categories

(2012) Jan J. Cornelissen et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

(2012) Hagop M. Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison

(2012) A K Burnett et al.   LEUKEMIA

The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach

(2012) Jan J. Cornelissen et al.   Nature Reviews Clinical Oncology

Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML)

(2011) Friederike Schneider et al.   ANNALS OF HEMATOLOGY

Most 70- to 79-year-old patients with acute myeloid leukemia do benefit from intensive treatment

(2011) G. Juliusson et al.   BLOOD

Applicability of a "Pick a Winner" trial design to acute myeloid leukemia

(2011) R. K. Hills et al.   BLOOD

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category

(2011) K. H. Metzeler et al.   BLOOD

TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics

(2011) W.-C. Chou et al.   BLOOD

Acute myeloid leukaemia in the elderly: a review

(2011) Daniel A. Pollyea et al.   BRITISH JOURNAL OF HAEMATOLOGY

Older Patients With Acute Myeloid Leukemia Benefit From Intensive Chemotherapy: An Update From the Swedish Acute Leukemia Registry

(2011) Gunnar Juliusson   Clinical Lymphoma Myeloma & Leukemia

Prediction of Early Death After Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia With Pretreatment Risk Scores: A Novel Paradigm for Treatment Assignment

(2011) Roland B. Walter et al.   JOURNAL OF CLINICAL ONCOLOGY

Therapeutic Advances in Acute Myeloid Leukemia

(2011) Alan Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience

(2010) B. C. Medeiros et al.   BLOOD

FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

(2010) S. P. Whitman et al.   BLOOD

A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial

(2010) C. Rollig et al.   BLOOD

HighEVI1Expression Predicts Outcome in Younger Adult Patients With Acute Myeloid Leukemia and Is Associated With Distinct Cytogenetic Abnormalities

(2010) Stefan Gröschel et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of Complete Remission and Responses Less Than Complete Remission on Survival in Acute Myeloid Leukemia: A Combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study

(2010) Roland B. Walter et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

(2010) W. Blum et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

AML at older age: age-related gene expression profiles reveal a paradoxical down-regulation of p16INK4A mRNA with prognostic significance

(2009) H. J. M. de Jonge et al.   BLOOD

Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome

(2009) B. J. Wouters et al.   BLOOD

Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials

(2009) Keith Wheatley et al.   BRITISH JOURNAL OF HAEMATOLOGY

Age-Specific Differences in Oncogenic Pathway Dysregulation in Patients With Acute Myeloid Leukemia

(2009) Arati V. Rao et al.   JOURNAL OF CLINICAL ONCOLOGY

Favorable Prognostic Impact ofNPM1Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study

(2009) Heiko Becker et al.   JOURNAL OF CLINICAL ONCOLOGY

Acute Myeloid Leukemia With Biallelic CEBPA Gene Mutations and Normal Karyotype Represents a Distinct Genetic Entity Associated With a Favorable Clinical Outcome

(2009) Annika Dufour et al.   JOURNAL OF CLINICAL ONCOLOGY

Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

(2009) Pierre Fenaux et al.   JOURNAL OF CLINICAL ONCOLOGY

High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia

(2009) Bob Löwenberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry

(2008) G. Juliusson et al.   BLOOD

High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated

(2008) S. Lugthart et al.   BLOOD

Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005

(2008) A. R. Derolf et al.   BLOOD

Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia

(2008) J.-V. Malfuson et al.   HAEMATOLOGICA

Monosomal Karyotype in Acute Myeloid Leukemia: A Better Indicator of Poor Prognosis Than a Complex Karyotype

(2008) Dimitri A. Breems et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia

(2008) Richard F. Schlenk et al.   NEW ENGLAND JOURNAL OF MEDICINE